Drug intelligence / Profile preview

cu-cyclam

Development stage
Preclinical
Modality
Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous (for Radiolabeled Forms Used In Imaging/therapy)[6]
01

Overview

Cu-Cyclam is a coordination complex consisting of a copper(II) ion chelated by the macrocyclic ligand cyclam (1,4,8,11-tetraazacyclotetradecane). Cyclam is a 14-membered tetraamine macrocycle that binds strongly to transition metal ions such as copper. The Cu-Cyclam complex has been studied primarily as an experimental agent and is not approved for clinical use. Its main interest lies in its ability to form highly stable complexes with copper(II), which can be exploited for various biomedical applications including radiopharmaceuticals (e.g., PET imaging agents using radioactive isotopes like ^64Cu), targeted cancer therapy (as in αVβ3 integrin-targeted radionuclide therapy), and as model compounds for studying redox processes and metalloprotein mimics[1][3][6]. Mechanistically, Cu-Cyclam may interact with biological targets such as lysozyme C but its precise pharmacological action remains unclear[1]. The stability of the Cu-cyclam complex makes it useful in nuclear medicine and diagnostic imaging[7][9].

Other names
copper(II)-cyclam[Cu(cyclam)]2+copper-1,4,8,11-tetraazacyclotetradecane
02

Targets

LYZ (Lysozyme C)

Beyond the preview

Go deeper on cu-cyclam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cu-cyclam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call